品牌 | 货号 | 包装单位 | 货期 | CAS | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|---|
麦克林 | L832989-10mg | 10mg | 现货 | 154447-36-6 |
LY294002 LY294002 |
≥98% |
|
|
麦克林 | L832989-50mg | 50mg | 现货 | 154447-36-6 |
LY294002 LY294002 |
≥98% |
|
|
麦克林 | L832989-250mg | 250mg | 现货 | 154447-36-6 |
LY294002 LY294002 |
≥98% |
|
|
麦克林 | L797081-1ml | 1ml | 现货 | 154447-36-6 |
LY294002 LY294002 干冰运输(加收0元干冰费用) |
10mM in DMSO |
|
|
阿拉丁 | L124970-10mg | 10mg | 现货 | 154447-36-6 |
2-吗啉代-8-苯基色酮 LY294002 |
Moligand™, ≥98% |
|
|
阿拉丁 | L124970-50mg | 50mg | 现货 | 154447-36-6 |
2-吗啉代-8-苯基色酮 LY294002 |
Moligand™, ≥98% |
|
|
阿拉丁 | L124970-25mg | 25mg | 现货 | 154447-36-6 |
2-吗啉代-8-苯基色酮 LY294002 |
Moligand™, ≥98% |
|
|
阿拉丁 | L124970-100mg | 100mg | 现货 | 154447-36-6 |
2-吗啉代-8-苯基色酮 LY294002 |
Moligand™, ≥98% |
|
|
阿拉丁 | L124970-250mg | 250mg | 现货 | 154447-36-6 |
2-吗啉代-8-苯基色酮 LY294002 |
Moligand™, ≥98% |
|
|
阿拉丁 | L124970-500mg | 500mg | 现货 | 154447-36-6 |
2-吗啉代-8-苯基色酮 LY294002 |
Moligand™, ≥98% |
|
|
阿拉丁 | L276596-1ml | 1ml | 现货 | 154447-36-6 |
LY 294002(DMSO溶液) LY 294002 (DMSO solution) |
Moligand™, ≥98%, 10mM in DMSO |
|
|
罗恩 |
R019092-10mg 当天发货 |
10mg | 现货 | 154447-36-6 |
2-吗啉代-8-苯基色酮 LY294002 |
98% |
|
|
罗恩 |
R019092-50mg 当天发货 |
50mg | 现货 | 154447-36-6 |
2-吗啉代-8-苯基色酮 LY294002 |
98% |
|
|
百灵威 | 284107-5MG | 5MG | 1-3天 | 154447-36-6 |
2-吗啉代-8-苯基色酮 2-Morpholino-8-phenylchromon... |
98% |
|
|
百灵威 | 284107-25MG | 25MG | 1-3天 | 154447-36-6 |
2-吗啉代-8-苯基色酮 2-Morpholino-8-phenylchromon... |
98% |
|
|
毕得 | BD136896-50mg | 50mg | 现货 | 154447-36-6 |
2-吗啉-8-苯基-4H-苯并吡喃-4-酮 2-Morpholino-8-phenyl-4H-chr... |
98% |
|
|
毕得 | BD136896-100mg | 100mg | 现货 | 154447-36-6 |
2-吗啉-8-苯基-4H-苯并吡喃-4-酮 2-Morpholino-8-phenyl-4H-chr... |
98% |
|
|
毕得 | BD136896-250mg | 250mg | 现货 | 154447-36-6 |
2-吗啉-8-苯基-4H-苯并吡喃-4-酮 2-Morpholino-8-phenyl-4H-chr... |
98% |
|
|
毕得 | BD136896-1g | 1g | 现货 | 154447-36-6 |
2-吗啉-8-苯基-4H-苯并吡喃-4-酮 2-Morpholino-8-phenyl-4H-chr... |
98% |
|
|
梯希爱 | M2410-25MG | 25MG | 现货 | 154447-36-6 |
2-吗啉代-8-苯基色酮 2-Morpholino-8-phenylchromon... |
98.0% |
|
|